What the research found
Testosterone circulates in women's bodies in meaningful quantities—roughly four times more than estrogen—yet clinical understanding of its role has historically centered on men. The hormone influences muscle and bone density, sexual function, mood, cognition, metabolism, and cardiovascular health. It's produced primarily in the ovaries and adrenal glands and sits upstream in the steroid synthesis pathway, meaning it converts into estrogen rather than operating as an isolated molecule.
The evidence base for testosterone therapy in women is narrow. Clinical consensus exists only for hypoactive sexual desire disorder (HSDD), supported by randomized trial data and endorsed by major medical bodies. However, a randomized controlled trial in women with chronic heart failure found that testosterone patches improved aerobic capacity, walking distance, muscle strength, and insulin sensitivity over six months—suggesting physiological effects extend well beyond sexual function, though this remains a single relatively small study rather than a replicated finding across multiple sites.
Symptom patterns, not laboratory values, should guide treatment decisions. No testosterone threshold reliably predicts sexual dysfunction across any age group; women with low levels may be asymptomatic, while those with normal lab values may report significant distress. The practical role of baseline testing is to confirm you aren't already elevated before adding more hormone, and to measure free testosterone and SHBG (sex hormone-binding globulin) specifically, since rising SHBG during menopause can trap testosterone and amplify symptom severity even when total testosterone appears adequate.
Why it matters for you
If you're tracking energy, mood, or sexual function alongside your other biomarkers, testosterone deserves the same attention as estrogen or thyroid markers. Many women describe fatigue that sleep doesn't resolve, flattened motivation, or mood changes and never consider hormonal contribution because testosterone has been categorized as "male." Measuring both free and total testosterone with high-precision testing (LC-MS/MS, not immunoassay) gives you clearer data than reference ranges alone, especially around perimenopause when SHBG changes can mask the functional picture.
If you're strength training or focusing on body composition, testosterone affects muscle recovery and bone density in women as meaningfully as in men, yet gets overlooked in female-focused programming. Similarly, if you monitor cardiovascular metrics or metabolic markers like insulin sensitivity, testosterone has documented effects on both. The takeaway: don't assume a "normal" lab result resolves symptoms like persistent fatigue or mood changes if your free testosterone is low relative to your SHBG.
Before attributing low energy or mood symptoms to testosterone, rule out overlapping causes—sleep apnea, iron deficiency, thyroid dysfunction, or depression—since these produce identical symptom clusters and require different interventions.
Caveats
- The heart failure trial was a single small study, not replicated across multiple research sites; promising but not yet proof at scale
- No standardized threshold exists for what constitutes "low" testosterone in women; clinical application relies on symptoms rather than numbers
- The field lacks large, long-term randomized trials examining testosterone therapy for fatigue, mood, or metabolic outcomes in women
- Most clinical guidelines remain narrow (HSDD only), reflecting funding and regulatory pathways rather than biological reality
- Immunoassay testosterone testing is unreliable at female concentrations and can give false reassurance